- Roche Holdings AG RHHBY said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease.
- Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function.
- The Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial evaluated the potential of crenezumab in 252 people.
- Minor numerical differences favoring crenezumab were observed across the co-primary and multiple secondary and exploratory endpoints, but these were not statistically significant.
- No new safety issues were identified. Further analyses of data are ongoing.
- Initial data will be presented at the Alzheimer's Association International Conference in August.
- Within its Alzheimer's pipeline, Roche is also evaluating gantenerumab in autosomal dominant Alzheimer's disease, as well as for preventing sporadic Alzheimer's and treating early Alzheimer's in late-stage trials.
- The phase 3 GRADUATE studies results of gantenerumab in early Alzheimer's are expected in Q4, 2022.
- Crenezumab is an investigational treatment discovered by AC Immune SA ACIU and designed to neutralize a pathological species of the beta-amyloid protein called oligomers.
- It was developed by Genentech, a member of the Roche Group, under a license and collaboration agreement established in 2006.
- Price Action: ACIU shares are down 27.62% at $2.07 during the premarket session on the last check Thursday. RHHBY shares closed at $38.53 on Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: BiotechLarge CapNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving